Recent Investment Analysts’ Ratings Updates for Solventum (SOLV)

Solventum (NYSE: SOLV) has recently received a number of price target changes and ratings updates:

• 2/28/2026 – Solventum was upgraded by Wall Street Zen from “hold” to “buy”.
• 2/27/2026 – Solventum had its price target lowered by Wells Fargo & Company from $86.00 to $83.00. They now have an “equal weight” rating on the stock.
• 2/27/2026 – Solventum had its price target raised by KeyCorp from $97.00 to $99.00. They now have an “overweight” rating on the stock.
• 2/27/2026 – Solventum had its “buy” rating reaffirmed by BTIG Research. They now have a $100.00 price target on the stock.
• 2/7/2026 – Solventum was downgraded by Wall Street Zen from “buy” to “hold”.
• 1/27/2026 – Solventum had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 1/26/2026 – Solventum was upgraded by KeyCorp from “sector weight” to “overweight”. They now have a $97.00 price target on the stock.
• 1/20/2026 – Solventum was given a new $100.00 price target by Mizuho. They now have an “outperform” rating on the stock.
• 1/20/2026 – Solventum was upgraded by Mizuho from “neutral” to “outperform”. They now have a $100.00 price target on the stock, up from $85.00.
• 1/7/2026 – Solventum had its price target raised by Stifel Nicolaus from $88.00 to $105.00. They now have a “buy” rating on the stock.

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.